- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03987282
Implementation of STTR Strategies Among People Who Inject Drugs in Malaysia
Implementation of Seek, Test, Treat & Retain Strategies Among People Who Inject Drugs in Malaysia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At each of the study locations, individuals testing HIV positive who also have OUD (n=4x70) will receive concurrent anti-retroviral therapy (ART) and methadone maintenance treatment (MMT) based on the usual care standards. Their patient level outcomes will be compared with individuals meeting the same inclusion criteria (n=4x70) and treated under the proposed improved model (post implementation evaluation). The usual care standard will consist of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT). The improved care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT. The primary outcome measure, rates of patients with virologic suppression (< 20 copies/mL) in the two care models will be assessed at 24 weeks. The secondary outcomes, also followed for 24 weeks, will include ART adherence measured by objective measures (tenofovir dried blood spots, clinic records) and self-report; decreased illicit opioid use measured by rates of opioid negative urine toxicology results and self-report; and improvements on other health-related and functional status outcomes.
Aim 1: To evaluate comparative effectiveness of fully implemented seek, test, treat and retain strategy (FI-STTR) the study will compare clinical, patient level, outcomes between enhanced usual care (EUC) and FI-STTR across the four study sites.
Hypothesis: The investigators hypothesize a statistically significant effect on the primary outcome favoring the FI-STTR over EUC. It is also hypothesized that FI-STTR will be superior over EUC on all secondary outcomes.
Concurrently at each study location, using implementation science mixed methods research tools and engaging key local stakeholders (treatment providers, patients, their families, and community activists), and evaluating clinical and healthcare data, the study will assess existing barriers (organizational, personnel, and community level factors) and uncover available resources and facilitators for a successful implementation of the improved care model.
Aim 2: To assess existing barriers; organizational, personnel, community level factors; and available resources and potentially facilitating factors for successful implementation of the FI-STTR at HIV/AIDS clinics. There are no hypotheses specified a priori for Aim 2 of the proposed study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marek C Chawarski, PhD
- Phone Number: 2039747602
- Email: marek.chawarski@yale.edu
Study Locations
-
-
Penang
-
Gelugor, Penang, Malaysia, 11800
- Recruiting
- Universiti Sains Malalysia
-
Contact:
- Vicknasingam Kasinather, PhD
- Phone Number: 604 6532140
- Email: vickna@usm.my
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- potential participants must meet the inclusion criteria for ART and MMT and begin receiving these treatments
Exclusion Criteria:
- ART and MMT exclusion criteria include: liver enzymes greater than 5 times the upper limit of normal (ULN); liver failure (Childs Pugh Turcot Grade B or C).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Enhanced usual care (EUC)
The EUC consists of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
|
Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
|
Experimental: Fully Implemented Seek-Test-Treat-Retain (FI-STTR) model
The FI-STTR care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention
|
Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
Peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Virologic suppression
Time Frame: 24 weeks
|
The rates of patients with virologic suppression (< 20 copies/mL) in the two care models will be assessed at 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ART adherence, proportion of days when medication is taken as prescribed
Time Frame: 24 weeks
|
ART adherence will be assessed by self-report using a timeline follow back (TLFB) methodology
|
24 weeks
|
Opioid use
Time Frame: 24 weeks
|
Illicit opioid use measured by rates of opioid negative urine toxicology results and self-report
|
24 weeks
|
Depression scores
Time Frame: 24 weeks
|
Center for Epidemiological Studies Depression Scale (CES-D) total score.
The scale range is from 0 to 60; higher scores indicate more depression symptoms.
|
24 weeks
|
Psychiatric symptoms
Time Frame: 24 weeks
|
Brief Symptom Inventory (BSI) a 53-item self-report inventory in which participants rate the extent to which they have been bothered (0 ="not at all" to 4="extremely") in the past week by various symptoms.
The BSI has nine subscales designed to assess individual symptom groups: somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism.
Higher scores indicate higher severity of symptoms.
|
24 weeks
|
Changes in the quality of life index
Time Frame: 24 weeks
|
Short version of the World Health Organization Quality of Life (WHOQOL-BREF).
The WHOQOL-BREF contains a total of 26 questions.
In addition, two items from the Overall quality of Life and General Health facet are included.
Four domains are assessed: Physical, Psychological, Social Relationship, and Environment.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marek C Chawarski, PhD, Yale School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Narcotic-Related Disorders
- HIV Infections
- Urogenital Diseases
- Genital Diseases
- HIV Seropositivity
- Opioid-Related Disorders
Other Study ID Numbers
- 2000023790
- 1R01DA047789-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Seropositivity
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Therapeutic ConceptsJanssen Scientific Affairs, LLCUnknown
Clinical Trials on Enhanced usual care (EUC)
-
Jeff BridgeCenters for Disease Control and PreventionRecruitingInsomnia | Suicidal Ideation | Suicide, AttemptedUnited States
-
Albert Einstein College of MedicineColumbia University; University of Rochester; Rutgers UniversityCompletedPediatric Obesity | Early Childhood CariesUnited States
-
University of North Carolina, Chapel HillUniversity of Houston; Colorado School of Public Health; University of North... and other collaboratorsEnrolling by invitationChild Behavior DisordersIndia
-
VA Office of Research and DevelopmentCompletedPTSD | Posttraumatic Stress DisorderUnited States
-
Ohio State UniversityNot yet recruitingPostpartum Depression | Postpartum Anxiety | Cardiometabolic SyndromeUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Not yet recruitingSuicidal Ideation | Suicide | Suicide PreventionPakistan
-
Massachusetts General HospitalNational Cancer Institute (NCI); Harvard Risk Management FoundationCompletedCancer | Breast Cancer | Head and Neck Cancer | Schizophrenia | Lung Cancer | Bipolar Disorder | Gastrointestinal Cancer | Severe Major DepressionUnited States
-
VA Office of Research and DevelopmentCompleted
-
University of North Carolina, Chapel HillUniversity of Colorado, Denver; American Academy of Child Adolescent Psychiatry... and other collaboratorsCompletedChild Behavior DisordersIndia
-
University of AarhusKarolinska University Hospital; Aarhus University Hospital; National Research...CompletedAcceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic SyndromesSomatoform Disorders | Somatization DisorderDenmark